Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 143

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 143
---
,058,025 |   |     |             |             |   |    |     |                |  14,706,847 |   |
| Basic and diluted net                            
 loss per share                                   |     | $                  |      (0.39 | ) |     | $             |      (0.80 | ) |     |             |             |   |    |     | $              |       (3.73 | ) |
| Basic and diluted weighted                       
 average shares outstanding, Class B Common Stock |     |                    |  2,304,421 |   |     |               |        N/A |   |     |             |             |   |    |     |                |         N/A |   |
| Basic and diluted net                            
 loss per share                                   |     | $                  |      (0.39 | ) |     |               |        N/A |   |     |             |             |   |    |     |                |         N/A |   |

<div align='center'>78

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</div>

Note 1. Basis of Presentation

The Business Combination
is being accounted for as an asset acquisition in accordance with U.S. GAAP. Under this method of accounting, PBAX will be treated as
the “accounting acquirer” and Legacy CERo as the “accounting acquiree” for financial reporting purposes. Accordingly,
for accounting purposes, the Business Combination is being accounted for as an asset acquisition as substantially all of the fair value
is concentrated in IPR&D, an intangible asset. Legacy CERo’s assets (except for cash) and liabilities will be measured and
recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated
with IPR&D with no alternative future use being expensed. The fair value measurements utilize estimates based on key assumptions
of the Business Combination, including historical and current market data.

The unaudited pro forma
adjustments included herein are preliminary and will be adjusted as additional information becomes available and as additional analyses
are performed. The final purchase price allocation will be determined subsequent to the Merger, and the final amounts of the assets acquired,
and liabilities assumed may differ materially from the values recorded in the pro forma financial information.

The unaudited pro forma
condensed combined balance sheet as of December 31, 2023, gives effect to the